{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:45:24Z","timestamp":1790793924295,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.neuropharm.2016.02.011","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T06:28:36Z","timestamp":1455690516000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Metabotropic glutamate receptors in cancer"],"prefix":"10.1016","volume":"115","author":[{"given":"Lumeng J.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Wangari-Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.02.011_bib1","doi-asserted-by":"crossref","first-page":"e103204","DOI":"10.1371\/journal.pone.0103204","article-title":"Identification of novel GRM1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues","volume":"9","author":"Ali","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.0b013e3182088273","article-title":"White matter synapses: form, function, and dysfunction","volume":"76","author":"Alix","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1215\/S1152851704000961","article-title":"Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in\u00a0vivo","volume":"7","author":"Arcella","year":"2005","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib4","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1046\/j.1460-9568.2003.02657.x","article-title":"Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins","volume":"17","author":"Aronica","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1471-4159.1997.69010151.x","article-title":"Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation","volume":"69","author":"Balazs","year":"1997","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib6","first-page":"99","article-title":"Radiotherapy for cutaneous malignant melanoma: rationale and indications","volume":"18","author":"Ballo","year":"2004","journal-title":"Oncol. Williston Park"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijrobp.2005.06.030","article-title":"Combined-modality therapy for patients with regional nodal metastases from melanoma","volume":"64","author":"Ballo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib8","doi-asserted-by":"crossref","first-page":"e81126","DOI":"10.1371\/journal.pone.0081126","article-title":"Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer","volume":"9","author":"Banda","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib9","first-page":"830","article-title":"The radiation response of human malignant melanoma cells grown in\u00a0vitro","volume":"31","author":"Barranco","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4161\/cbt.9.6.10898","article-title":"Glutamate receptors in pediatric tumors of the central nervous system","volume":"9","author":"Brocke","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib12","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.4049\/jimmunol.163.4.2017","article-title":"Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor","volume":"163","author":"Burger","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib13","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1093\/emboj\/19.12.2900","article-title":"Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes","volume":"19","author":"Busca","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib15","series-title":"Treatment of Metastatic Melanoma","article-title":"Diagnosis and treatment options for brain metastasis of melanoma","author":"Chaichana","year":"2011"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib16","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/1078-0432.CCR-04-1912","article-title":"Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance","volume":"11","author":"Chang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1523-1747.ep12340194","article-title":"Spontaneous melanocytosis in transgenic mice","volume":"106","author":"Chen","year":"1996","journal-title":"J.\u00a0Investig. Dermatol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1541-7786.MCR-07-2203","article-title":"Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion","volume":"6","author":"Cheng","year":"2008","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0306-4522(02)00318-4","article-title":"Regulation of transcription factor phosphorylation by metabotropic glutamate receptor-associated signaling pathways in rat striatal neurons","volume":"114","author":"Choe","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib20","doi-asserted-by":"crossref","first-page":"15219","DOI":"10.1073\/pnas.1107304108","article-title":"Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/cdd.2012.150","article-title":"Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas","volume":"20","author":"Ciceroni","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1046\/j.1471-4159.2003.01633.x","article-title":"Pharmacological blockade of mGlu2\/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells","volume":"84","author":"D'Onofrio","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib23","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.3390\/ijms15058773","article-title":"In\u00a0vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways","volume":"15","author":"Daphu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib24","doi-asserted-by":"crossref","first-page":"19345","DOI":"10.1073\/pnas.0709747104","article-title":"Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis","volume":"104","author":"DeBerardinis","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.gde.2008.02.003","article-title":"Brick by brick: metabolism and tumor cell growth","volume":"18","author":"Deberardinis","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib26","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1158\/1078-0432.CCR-06-0439","article-title":"A\u00a0mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis","volume":"12","author":"Degenhardt","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00101-007-1289-3","article-title":"Basal tako-tsubo cardiomyopathy. Induction of a pheochromocytoma after general anesthesia","volume":"57","author":"Dimski","year":"2008","journal-title":"Anaesthesist"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib28","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1215\/15228517-2007-015","article-title":"Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate","volume":"9","author":"Eichler","year":"2007","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4161\/sgtp.24304","article-title":"Regulation of G protein-coupled receptor trafficking and signaling by Rab GTPases","volume":"4","author":"Esseltine","year":"2013","journal-title":"Small GTPases"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/10408360500523878","article-title":"Glutathione in cancer biology and therapy","volume":"43","author":"Estrela","year":"2006","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1098-2388(199611\/12)12:6<429::AID-SSU8>3.0.CO;2-C","article-title":"Treatment of melanoma metastases in the brain","volume":"12","author":"Ewend","year":"1996","journal-title":"Semin. Surg. Oncol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib33","first-page":"F481","article-title":"Functional diversity of excitatory amino acid transporters: ion channel and transport modes","volume":"277","author":"Fairman","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib35","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/ncomms3236","article-title":"Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells","volume":"4","author":"Fendt","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib36","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1046\/j.1460-9568.1999.00626.x","article-title":"Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors","volume":"11","author":"Ferraguti","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib37","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/pcmr.12000","article-title":"Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma","volume":"25","author":"Filipp","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib38","first-page":"656","article-title":"Expression of metabotropic glutamate receptor and phosphorylated extracellular signal-regulated kinase 1\/2 proteins in human melanocytic lesions","volume":"19","author":"Funasaka","year":"1996","journal-title":"Pigment Cell Res. Spons. Eur. Soc. Pigment Cell Res. Int. Pigment Cell Soc."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib39","doi-asserted-by":"crossref","first-page":"e4715","DOI":"10.1371\/journal.pone.0004715","article-title":"Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts","volume":"4","author":"Gaglio","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cmet.2013.02.002","article-title":"In\u00a0vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation","volume":"17","author":"Gameiro","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib41","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bcp.2015.08.091","article-title":"Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells","volume":"98","author":"Gelb","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib43","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1038\/onc.2014.231","article-title":"Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas","volume":"34","author":"Gelb","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00005792-198501000-00002","article-title":"Cerebrovascular complications in patients with cancer","volume":"64","author":"Graus","year":"1985","journal-title":"Med. Baltim."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib45","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1073\/pnas.88.11.4703","article-title":"Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes","volume":"88","author":"Gutkind","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib46","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/1097-0142(197612)38:6<2258::AID-CNCR2820380611>3.0.CO;2-H","article-title":"Radiation therapy of malignant melanoma: experience with high individual treatment doses","volume":"38","author":"Habermalz","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib47","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1523\/JNEUROSCI.2285-06.2006","article-title":"Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas","volume":"26","author":"Iacovelli","year":"2006","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib48","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.2727693","article-title":"Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation","volume":"244","author":"Julius","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.tibs.2015.04.002","article-title":"Emerging structural insights into the function of ionotropic glutamate receptors","volume":"40","author":"Karakas","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mrdd.1040","article-title":"Disorders of glutamate metabolism","volume":"7","author":"Kelly","year":"2001","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib51","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-10-1276","article-title":"Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in\u00a0vitro and in\u00a0vivo","volume":"17","author":"Khan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/aja.2012.145","article-title":"Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer","volume":"15","author":"Koochekpour","year":"2013","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib54","doi-asserted-by":"crossref","first-page":"e80773","DOI":"10.1371\/journal.pone.0080773","article-title":"The role of metabotropic glutamate receptor 5 on the stromal cell-derived factor-1\/CXCR4 system in oral cancer","volume":"8","author":"Kuribayashi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib55","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-11-0098","article-title":"Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies","volume":"17","author":"Lee","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib56","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4110\/in.2011.11.6.420","article-title":"CKD-712, (S)-1-(alpha-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, inhibits the NF-kappaB activation and augments Akt activation during TLR4 signaling","volume":"11","author":"Lee","year":"2011","journal-title":"Immune Netw."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib57","doi-asserted-by":"crossref","first-page":"10775","DOI":"10.1074\/jbc.M115.644773","article-title":"G\u00a0protein-coupled receptor kinases of the GRK4 protein subfamily phosphorylate inactive G protein-coupled receptors (GPCRs)","volume":"290","author":"Li","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib58","first-page":"365","article-title":"Brain tumors with hemorrhage","volume":"98","author":"Lieu","year":"1999","journal-title":"J.\u00a0Formos. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ana.410010112","article-title":"Alzheimer neurofibrillary change in subacute sclerosing panencephalitis","volume":"1","author":"Mandybur","year":"1977","journal-title":"Ann. Neurol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2016.02.011_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/S1807-59322011001300005","article-title":"Metabolism and brain cancer","volume":"66","author":"Marie","year":"2011","journal-title":"Clin. Sao Paulo"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00109-004-0566-8","article-title":"Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development","volume":"82","author":"Marin","year":"2004","journal-title":"J.\u00a0Mol. Med. Berl."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib62","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cellsig.2005.10.012","article-title":"Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1\/2 via PKCepsilon","volume":"18","author":"Marin","year":"2006","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib63","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1038\/onc.2012.471","article-title":"Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells","volume":"32","author":"Martino","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0360-3016(94)E0147-C","article-title":"The spectrum of in\u00a0vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks","volume":"31","author":"McKay","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib65","unstructured":"Mehnert, J.M., Wen, Y., Lee, J.H., Jeong, B.S., Li, J., Dudek, Pruski-Clark, L.L, Kane, M.M., Lin, H., Shih, W., Chen, S., Goydos, J.S., 2016. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib66","doi-asserted-by":"crossref","first-page":"e69851","DOI":"10.1371\/journal.pone.0069851","article-title":"Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes","volume":"8","author":"Mehta","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib67","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/088307389901400308","article-title":"Carrell-Krusen symposium invited lecture. Clinical trials in motor neuron diseases","volume":"14","author":"Miller","year":"1999","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib68","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1016\/S0021-9258(20)82128-0","article-title":"The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme","volume":"259","author":"Moreadith","year":"1984","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib69","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0014-5793(93)80278-3","article-title":"Excitatory amino acid-induced slow biphasic responses of free intracellular calcium in human neuroblastoma cells","volume":"330","author":"Naarala","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib71","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-06-3665","article-title":"Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma","volume":"67","author":"Namkoong","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib72","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11864-013-0228-6","article-title":"Metastatic melanoma to the brain: surgery and radiation is still the standard of care","volume":"14","author":"Nicholas","year":"2013","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib73","first-page":"109","article-title":"Metabolic flux analysis in systems biology of mammalian cells","volume":"127","author":"Niklas","year":"2012","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib74","doi-asserted-by":"crossref","first-page":"82","DOI":"10.18632\/oncoscience.11","article-title":"Melanoma brain colonization involves the emergence of a brain-adaptive phenotype","volume":"1","author":"Nygaard","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib75","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1038\/onc.2008.329","article-title":"Metabotropic glutamate receptor subtype-1 is essential for in\u00a0vivo growth of melanoma","volume":"27","author":"Ohtani","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib76","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/sj.ejhg.5201887","article-title":"Genetic analysis of the GRM1 gene in human melanoma susceptibility","volume":"15","author":"Ortiz","year":"2007","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib77","first-page":"81","article-title":"Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma","volume":"17","author":"Park","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib78","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0306-4522(95)00533-1","article-title":"The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations","volume":"71","author":"Petralia","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib79","first-page":"371","article-title":"The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells","volume":"29","author":"Pissimissis","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib80","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng1148","article-title":"Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia","volume":"34","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib81","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-11-1217","article-title":"Molecular pathways: dysregulated glutamatergic signaling pathways in cancer","volume":"18","author":"Prickett","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib82","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/ng.950","article-title":"Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma","volume":"43","author":"Prickett","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib83","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/187152710793361612","article-title":"Group I metabotropic glutamate receptor signalling and its implication in neurological disease","volume":"9","author":"Ribeiro","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib84","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib85","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/ng.2645","article-title":"Genome-wide association study identifies two susceptibility loci for osteosarcoma","volume":"45","author":"Savage","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib86","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1755-148X.2008.00452.x","article-title":"Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation","volume":"21","author":"Shin","year":"2008","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12640-011-9285-4","article-title":"The role of glutamate dehydrogenase in mammalian ammonia metabolism","volume":"21","author":"Spanaki","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib88","doi-asserted-by":"crossref","first-page":"e88830","DOI":"10.1371\/journal.pone.0088830","article-title":"Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer","volume":"9","author":"Speyer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib89","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10549-011-1624-x","article-title":"Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer","volume":"132","author":"Speyer","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib90","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00418-009-0613-1","article-title":"Expression of glutamate receptor subunits in human cancers","volume":"132","author":"Stepulak","year":"2009","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib91","first-page":"565","article-title":"Glutamate receptors in laryngeal cancer cells","volume":"31","author":"Stepulak","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cmet.2013.11.022","article-title":"Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth","volume":"19","author":"Sun","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib93","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/nm0901-1010","article-title":"Glutamate release promotes growth of malignant gliomas","volume":"7","author":"Takano","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib94","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter factor","volume":"94","author":"Takayama","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1755-148X.2012.00983.x","article-title":"Glutamatergic signaling in cellular transformation","volume":"25","author":"Teh","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib96","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/pcmr.12237","article-title":"Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor","volume":"27","author":"Teh","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib97","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1046\/j.1471-4159.2002.01217.x","article-title":"Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways","volume":"83","author":"Thandi","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib98","first-page":"186","article-title":"Advances in the surgical treatment of peptic ulcer","volume":"32","author":"Ti","year":"1977","journal-title":"Med. J. Malays."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib99","first-page":"249","article-title":"The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis","volume":"68","author":"Van den Bosch","year":"2006","journal-title":"Verh. K. Acad. Geneeskd. Belg."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib100","series-title":"Recent Advances in the Biology, Therapy and Management of Melanoma","article-title":"Glutamate signaling in human cancers","author":"Wall","year":"2013"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/pcmr.12207","article-title":"Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells","volume":"27","author":"Wall","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib102","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/pcmr.12327","article-title":"Riluzole is a radio-sensitizing agent in an in\u00a0vivo model of brain metastasis derived from GRM1 expressing human melanoma cells","volume":"28","author":"Wall","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib103","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1158\/0008-5472.CAN-13-1531","article-title":"Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression","volume":"74","author":"Wen","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib104","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7150\/ijbs.6426","article-title":"Glutamate, glutamate receptors, and downstream signaling pathways","volume":"9","author":"Willard","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib105","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib106","doi-asserted-by":"crossref","first-page":"19611","DOI":"10.1073\/pnas.1117773108","article-title":"Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability","volume":"108","author":"Wise","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib107","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6","article-title":"N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes","volume":"24","author":"Wroblewska","year":"1998","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2016.02.011_bib108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3171\/jns.2000.93.1.0009","article-title":"Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients","volume":"93","author":"Wronski","year":"2000","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib109","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-08-3303","article-title":"A\u00a0phase 0 trial of riluzole in patients with resectable stage III and IV melanoma","volume":"15","author":"Yip","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib110","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-1114-03","article-title":"Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line","volume":"10","author":"Yoo","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib111","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1586\/14737175.2015.1055321","article-title":"The current management of brain metastasis in melanoma: a focus on riluzole","volume":"15","author":"Yu","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib112","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.copbio.2010.08.009","article-title":"13C metabolic flux analysis in complex systems","volume":"22","author":"Zamboni","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib113","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000369707","article-title":"Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K\/Akt\/mTOR pathway","volume":"35","author":"Zhang","year":"2015","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1535-7163.MCT-11-0327","article-title":"Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R\/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines","volume":"11","author":"Zhao","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neuropharm.2016.02.011_bib115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1523-1747.1998.00133.x","article-title":"Development of heritable melanoma in transgenic mice","volume":"110","author":"Zhu","year":"1998","journal-title":"J.\u00a0Investig. Dermatol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816300466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816300466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T18:24:03Z","timestamp":1692210243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816300466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":114,"alternative-id":["S0028390816300466"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.02.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabotropic glutamate receptors in cancer","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}